Pharmaceutical composition capable of reducing complications and treating complex vascular malformation as well as preparation method and application of pharmaceutical composition

By mixing anhydrous ethanol with developer for vasculopathy treatment under DSA guidance, the complications and cumbersome steps in traditional methods are solved, and safer and more efficient vasculopathy embolization treatment is achieved, reducing patients' ray exposure and treatment costs.

CN118903070APending Publication Date: 2024-11-08SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410946138.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2021-02-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The current embolization sclerosis treatment of vascular malformations has complications such as tissue necrosis, nerve damage, muscle fibrosis, allergic shock, pulmonary artery spasm and cardiopulmonary crisis, and the traditional digital subtraction angiography technology has cumbersome steps and a long time. It is difficult to control the invisible injection of anhydrous ethanol.

Method used

Mix anhydrous ethanol with developer (such as iodine powder, iodine oil, tantalum powder) in proportion to be used for the treatment of complex vasculomorphism and embolization under DSA guidance to achieve the unity of contrast and treatment, dynamically monitor ethanol flow, and reduce Damage to normal tissue.

Benefits of technology

Shorten treatment steps and time, reduce complication rates, improve the safety and efficiency of treatment, and reduce the radiation exposure and treatment costs in patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004945689340000041
    Figure BDA0004945689340000041
  • Figure BDA0004945689340000042
    Figure BDA0004945689340000042
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition capable of reducing complications and treating complex vascular malformation. The pharmaceutical composition at least comprises absolute ethyl alcohol and a developing agent. According to the ethanol hardener applied to DSA-guided complicated vessel malformation embolism sclerosis treatment, absolute ethyl alcohol and a developing agent are mixed according to a ratio, radiography and treatment are carried out at the same time, the treatment steps are shortened, the time cost and the treatment cost are saved, and meanwhile ray exposure of a patient is reduced. In addition, compared with traditional invisible ethanol, the method is more controllable, the flow direction of the ethanol is dynamically monitored in the embolism process, the ethanol is prevented from flowing to normal tissue blood vessels, and therefore complications are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application based on the original application with application date of February 10, 2021, application number 202110184652.5, and invention name "A pharmaceutical composition for treating complex vascular malformations that can reduce complications, and its preparation method and application". Technical Field

[0002] The present invention relates to the field of interventional embolization and sclerosis treatment of complex vascular malformations, and in particular to a pharmaceutical composition for treating complex vascular malformations capable of reducing complications, and a preparation method and application thereof. Background Art

[0003] Hemangiomas and vascular malformations are common diseases caused by abnormal proliferation of endothelial cells or congenital malformation of blood vessels or lymphatic vessels. They often appear at birth and are prone to occur on the head and face, but can also affect the limbs and trunk. Hemangiomas and vascular malformations affect the appearance and bring huge life burdens to patients. In severe cases, they may even cause organ displacement, bone deformities, and functional disorders. Embolization sclerotherapy is currently the most widely used method for treating vascular malformations in clinical practice. There are many drugs used for sclerotherapy of hemangiomas and vascular malformations. The main sclerosants used include anhydrous ethanol, bleomycin (bleomycin), foam sclerosants (polidocanol, lauromacrogol, sodium tetradecyl sulfate), etc. The principle is to damage vascular endothelial cells and vascular wall structures, causing secondary coagulation and thrombosis, thereby leading to vascular atrophy and fibrosis, and reducing the size of lesions, but there is no consensus on the best agent internationally. Sclerotherapy has risks and complications, such as tissue necrosis, nerve damage, muscle fibrosis, anaphylactic shock, pulmonary artery spasm and embolism, cardiopulmonary crisis, and cerebral embolism.

[0004] Ethanol is a chemical sclerosant that can quickly destroy vascular endothelial cells and denature hemoglobin, leading to extensive thrombosis and fibrosis in blood vessels, promoting thrombosis of drainage veins and thrombosis in lesions. Anhydrous ethanol is effective in treating venous malformations and arteriovenous malformations, with a low recurrence rate and low price. However, due to its colorless and transparent nature, it is difficult to control and monitor during injection, which often leads to serious complications and adverse reactions, such as local swelling, tissue defect and death, and peripheral nerve damage. In recent years, digital subtraction angiography (DSA) technology has been widely used in embolization and sclerotherapy of vascular malformations. DSA technology has a wide field of view and clear imaging. In traditional DSA guidance technology, contrast agent is first injected after puncture to clarify the location and size of the lesion, and then the sclerosant is injected into the lesion cavity to replace the original contrast agent. Angiography and treatment are carried out in two steps, which are relatively cumbersome and time-consuming. Summary of the invention

[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a pharmaceutical composition for treating complex vascular malformations that can reduce complications, and a preparation method and application thereof.

[0006] A first aspect of the present invention provides a pharmaceutical composition for treating complex vascular malformations that can reduce complications, wherein the pharmaceutical composition comprises at least anhydrous ethanol and a developer.

[0007] The second aspect of the present invention provides a method for preparing a pharmaceutical composition for treating complex vascular malformations that can reduce complications, comprising preparing a mixture of anhydrous ethanol and a developer to obtain the pharmaceutical composition.

[0008] The third aspect of the present invention provides the use of the aforementioned pharmaceutical composition for treating complex vascular malformations capable of reducing complications in the preparation of a drug for embolic sclerosis treatment of vascular malformations.

[0009] The beneficial effects of the present invention are as follows: the present invention creates an ethanol hardener for embolization and sclerotherapy of complex vascular malformations under DSA guidance, mixes anhydrous ethanol with a developer (iodine powder, iodine oil, tantalum powder, etc.) according to a certain ratio, performs imaging and treatment at the same time, shortens the treatment steps, saves time and treatment costs, and reduces the radiation exposure of patients. In addition, the present invention is more controllable than traditional invisible ethanol, dynamically monitors the flow direction of ethanol during the embolization process, and prevents ethanol from flowing to normal tissues and blood vessels, thereby reducing complications.

[0010] The beneficial effects of mixing anhydrous ethanol and iodized oil: The iodized oil-anhydrous ethanol mixed emulsion can cause ethanol to remain in the local blood vessels for a longer period of time, making it less likely to be washed away by the high-velocity blood in the lesion, and the effect is relatively long-lasting; (2) The iodized oil-anhydrous ethanol mixed emulsion can reduce the penetration of anhydrous ethanol into the normal tissues around the lesion, thereby protecting the normal tissue function to the greatest extent. DETAILED DESCRIPTION

[0011] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0012] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0013] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0014] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0015] A pharmaceutical composition for treating complex vascular malformations capable of reducing complications according to an embodiment of the present invention comprises at least anhydrous ethanol and a developer.

[0016] In one embodiment, the developer is selected from iodine powder, iodized oil or tantalum powder.

[0017] In one embodiment, in the pharmaceutical composition, the mass ratio of anhydrous ethanol to the developer is 2:1-20:1, which can be adjusted according to the development requirements and embolization requirements.

[0018] In one embodiment, in the pharmaceutical composition, the mass ratio of anhydrous ethanol to the developer is 5:1-15:1.

[0019] Optionally, the mass ratio of the anhydrous ethanol to the developer can also be 6:1, 8:1, 10:1, 12:1, 16:1, 18:1, or 20:1.

[0020] In the present invention, the addition of the developer does not change the concentration of anhydrous ethanol acting on the body.

[0021] Application of a pharmaceutical composition for treating complex vascular malformations capable of reducing complications in the preparation of a drug for embolic sclerosis treatment of vascular malformations.

[0022] The subject of the pharmaceutical composition of the present invention can be an animal, preferably a mammal, specifically a primate, such as a human, a monkey, etc.

[0023] Example 1: Pharmaceutical composition for treating complex vascular malformations capable of reducing complications

[0024] Prepare the mixture according to the following formula:

[0025] 2ml of anhydrous ethanol

[0026] Tantalum powder 1g

[0027] Example 2: Pharmaceutical composition for treating complex vascular malformations capable of reducing complications

[0028] Prepare the mixture according to the following formula:

[0029] Anhydrous ethanol 10ml

[0030] Iodine oil 1ml

[0031] Example 3: Pharmaceutical composition for treating complex vascular malformations capable of reducing complications

[0032] Prepare the mixture according to the following formula:

[0033] Anhydrous ethanol 10ml

[0034] Iodine powder 2g

[0035] Example 4: Pharmaceutical composition for treating complex vascular malformations capable of reducing complications

[0036] Prepare the mixture according to the following formula:

[0037] Anhydrous ethanol 40ml

[0038] Iodine powder 2g

[0039] Example 5 Clinical effect experiment

[0040] Twenty patients with vascular malformations were selected as volunteers and divided into two groups (group I and group II). The age, gender, number of treatments, duration of single treatment, postoperative follow-up time, etc. of the two groups were compared, and the adverse reactions and complications, as well as the efficacy evaluation (VAS score 0-6 points) were analyzed.

[0041] VAS score: The clinical efficacy was graded as follows: aggravated (0 points), no significant improvement (1 point), minimal improvement (0-25%, 2 points), mild improvement (25%-50%, 3 points), significant improvement (50%-75%, 4 points), significant improvement (75%-90%, 5 points), and almost completely cleared (90%-100%, 6 points). The final VAS score was recorded as the average of the two doctors' scores.

[0042] The details are as follows;

[0043] There were 10 patients in the anhydrous ethanol treatment group (group I) (traditional method); as shown in Table 1, there were 7 males and 3 females. The average age was 22.5 years (SD, 11.17). The average number of treatments was 6.2 (SD, 2.71), and the average follow-up time was 7.4 months (SD, 1.11). The average VAS score was 4.5 (SD, 1.28), and the average single treatment time was 54 minutes (SD, 8.93). Two of the 10 patients (20%) developed local superficial skin necrosis, which healed spontaneously after 4 weeks without residual tissue defects.

[0044]

[0045] 10 patients in the pharmaceutical composition treatment group (Group II) described in Example 2 of the present invention: The results are shown in Table 2. 10 patients; 6 males and 4 females. The average age was 18.6 years (SD, 14.65). The average number of treatments was 6.4 times (SD, 2.73), and the average follow-up time was 6.3 months (SD, 2.29). The average VAS score was 4.8 (SD, 0.75), the average single treatment time was 32.42 minutes (SD, 5.9), and the incidence of adverse reactions and complications was 0 in 9 patients.

[0046] Table 2

[0047]

[0048] The present invention has comparable efficacy to traditional methods in treating complex arteriovenous malformations, but is safer, can shorten treatment time (p < 0.001), reduce radiation exposure of patients, and reduce radiation damage to the body; the incidence of complications and adverse reactions is reduced, and there is also a difference in the incidence of complications between the two groups.

[0049] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. Use of a composition in the preparation of a drug for treating embolic sclerotherapy of complex vascular malformations to reduce complications, characterized in that: The composition is a suspension consisting of anhydrous ethanol and a developer, and the developer is selected from iodine powder.

2. The use according to claim 1, characterized in that In the pharmaceutical composition, the mass ratio of anhydrous ethanol to the developer is 2:1-20:

1.

3. The use according to claim 2, characterized in that In the pharmaceutical composition, the mass ratio of anhydrous ethanol to the developer is 5:1-15:1.